COMMUNIQUÉS West-GlobeNewswire

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
29/09/2025
RAPT on track to initiate trial this year SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on [...]
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
29/09/2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for [...]
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
29/09/2025
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and [...]
Applied Therapeutics Provides Update Following Meeting with FDA
29/09/2025
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today [...]
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
29/09/2025
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in [...]
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
29/09/2025
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study [...]
AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25
29/09/2025
Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six abstracts at the 2025 Annual [...]
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
29/09/2025
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and [...]
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
29/09/2025
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage [...]
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
29/09/2025
A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
29/09/2025
Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme 1 à 24,6 millions d’euros au 30 juin 2025 Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du [...]
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
29/09/2025
Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up [...]
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
29/09/2025
Next generation sustained-release formulations for a variety of peptides Executive summary first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for [...]
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
29/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
28/09/2025
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company [...]
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
28/09/2025
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher [...]
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
28/09/2025
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a [...]
Shape Therapeutics Announces Multiple Oral Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
26/09/2025
Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease SEATTLE, Sept. 26, 2025 (GLOBE [...]
Tekton Research Expands Clinical Network with Three New Sites, Five New Investigators, and CNS Thought Leader
26/09/2025
Growth supports Tekton’s strategic focus on CNS and Cardiometabolic research AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading multi-site clinical trial company, is proud to announce the [...]

Pages